FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody that specifically binds to the interleukin-4 alpha receptor, or an antigen-binding fragment thereof, a pharmaceutical composition for prevention or treatment of diseases associated with IL-4R-alpha, a nucleotide molecule for producing the above antibody, an expression vector for producing the above antibodies, a host cell for producing the above antibody, a method for producing the above antibody, the use of the antibody or an antigen-binding fragment or composition thereof in preparation of drugs for prevention or treatment of diseases associated with IL-4R-alpha.
EFFECT: invention expands the arsenal of agents that specifically bind to IL-4R-alpha.
15 cl, 9 dwg, 11 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
